$BMSN - OUR BUSINESS MODEL | REGEN BIOPHARMA, INC.

The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets.

Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma.